ArticleMolecular pharmaceutics2025
Sweetening the Deal: Sweetener-Based Ionic Liquid of Albendazole Significantly Enhances Its Solubility and Oral Bioavailability.
Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Albendazole (ABZ) is a hydrophobic and weakly basic anthelmintic benzimidazole with a very low (5%) oral bioavailability. Conversion of hydrophobic ionizable drugs such as ABZ into ionic liquids (ILs) or liquid salts is an emerging strategy for improving their solubility and oral bioavailability. To date, FDA-approved non-nutritive anionic sweeteners have not been evaluated for the development of ILs of weakly basic and hydrophobic drugs. Hence, we evaluated the ability of various anionic non-nutritive sweeteners, acesulfame potassium (ACE-K), saccharin sodium (SAC-Na), and cyclamate sodium (CYM-Na), to transform ABZ into an IL. Interestingly, only ACE-K, upon interaction with ABZ at the ABZ to ACE molar ratio of 1:2, converted ABZ into a room-temperature IL [ABZ-ACE (1:2) IL], whereas SAC-Na and CYM-Na yielded salts or coamorphous systems. The interaction of ABZ with anionic sweeteners was confirmed using FT-IR and NMR. Compared to pure ABZ, all ABZ-sweetener ILs/salts/coamorphous systems displayed a 1.2- to 2-fold decrease in Log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.